%0 Journal Article
%T Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy
%A Hidekatsu Yanai
%A Hiroki Adachi
%A Kouki Kakuta
%A Mariko Hakoshima
%J Journal of Clinical Medicine Research
%D 2018
%R https://doi.org/10.14740/jocmr3392w
%X Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are anti-diabetic drugs which improve blood glucose control by blocking reabsorption of glucose from the proximal tubule of kidney. Anti-atherosclerotic properties and cardiovascular protective effects of SGLT2i have been demonstrated by recent studies; however, the efficacy and safety of addition of SGLT2i to the intensive insulin therapy remain largely unknown.
%U https://www.jocmr.org/index.php/JOCMR/article/view/3392